NCT01950182: Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer

NCT01950182
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 3
Drug Category: Endocrine (Hormone) Therapy, Therapeutic Antibody, Chemotherapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 75 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: Patients must be HER2+ and ER+ and/or PR+
Exclusions: 
https://ClinicalTrials.gov/show/NCT01950182

Comments are closed.

Up ↑